Hepatic Echinococcosis
Conditions
Interventions
LAT group :In the esketamine pretreatment group LAT group,1 mg/kg esketamine was administered intravenously during anesthetic induction,
TIVA gruop: while the total intravenous anesthesia control group TIVA groupreceived an equivalent volume of normal saline at induction
Sponsors
Bayingolin Mongol Autonomous Prefecture People's Hospital
Eligibility
Sex/Gender
All
Age
22 Years to 68 Years
Inclusion criteria
Inclusion criteria: 1.Aged 22-68 years, ASA grade I-II; 2. Imaging-confirmed CE1/CE3a hepatic cystic echinococcosis (WHO-IWGE classification); 3. Child-Pugh grade A, ICGR15 <10%.
Exclusion criteria
Exclusion criteria: 1. Allergy to esketamine or any trial-related drugs; 2. Severe cardiac, pulmonary, or renal dysfunction (e.g., NYHA Class III-IV heart failure, FEV1 180/110 mmHg); 4. History of psychiatric disorders or long-term use of psychotropic medications; 5. Pregnant or lactating women; 6. Emergency surgery; 7. Preoperative ALT/AST >2× upper limit of normal (ULN); 8. Participation in other drug clinical trials within the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALT(Alanine aminotransferase);AST(Aspartate aminotransferase ); | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-1ß(Interleukin-1 beta );TNF-a(Tumor Necrosis Factor-alpha);MDA (Malondialdehyde);NF-?B (Nuclear Factor Kappa B ); | — |
Countries
China
Contacts
Public ContactZulhumar Reyim
Bayingolin Mongol Autonomous Prefecture People's Hospital
Outcome results
None listed